Peptain-1, injected systemically, crossed the blood-retinal barrier and protected retinal ganglion cells from death in two glaucoma models, offering a potential neuroprotective treatment approach.
Crosses blood-retinal barrierPeptain-1 reached the retina after simple abdominal injection — no eye surgery or drops needed — and protected nerve cells in two glaucoma models
What the researchers found
Peptain-1, a peptide with chaperone and anti-apoptotic properties, protected retinal ganglion cells (RGCs) from death in two rodent models of glaucoma. When injected into the abdomen, the peptide crossed the blood-retinal barrier and reached the retina.
Key results across models:
- In ischemia/reperfusion injury mice: peptain-1 inhibited RGC loss and improved impaired axonal transport
- In rats with 5 weeks of elevated eye pressure: peptain-1 significantly reduced both RGC death and axon loss, and partially restored mitochondrial COX 6b2 levels
- In cell culture and retinal explants: peptain-1 significantly reduced hypoxia-induced RGC death compared to scrambled peptide control
Why it matters
Glaucoma is the leading cause of irreversible blindness worldwide, and the only current treatment is lowering eye pressure — which doesn't work for everyone and doesn't directly protect the dying nerve cells. Peptain-1 represents a fundamentally different approach: directly protecting the retinal ganglion cells that glaucoma destroys. The fact that it works when injected systemically (not into the eye) and crosses the blood-retinal barrier makes it far more practical than eye-injection-only therapies.
The numbers in context
2 rodent models · 5 weeks elevated intraocular pressure · blood-retinal barrier crossing confirmed · RGC somas and axons protected · mitochondrial COX 6b2 partially restored · scrambled peptide control used
How the study worked
Multi-model preclinical study. Researchers tested peptain-1 in cultured rat retinal ganglion cells, rat retinal explants, a mouse ischemia/reperfusion injury model, and a rat model of chronic elevated intraocular pressure (5 weeks). Peptain-1 was administered via intraperitoneal injection. Retinal penetration was confirmed using a fluorescent-labeled version (Cy7 conjugate). RGC survival, axonal transport, and mitochondrial protein levels were measured.
Who was studied
Rodent models: mouse ischemia/reperfusion injury model and rat chronic elevated intraocular pressure model, plus cultured rat RGCs and retinal explants
What this study cannot tell us
Animal models only — rodent glaucoma models don't perfectly replicate the slow, chronic disease seen in humans over decades. Dosing details and duration of protective effect after stopping treatment were not described. Long-term safety of systemic peptain-1 was not assessed. The study doesn't address whether the peptide would work in human eyes, which have different blood-retinal barrier properties.
How to read the evidence
Moderate evidence from a well-designed preclinical study using multiple complementary models (cell culture, explants, two rodent models) with appropriate controls (scrambled peptide). The convergent results across models strengthen the findings. However, this remains animal research with no human data.
When this study was published
Published in 2019. Peptain-1 neuroprotection research has continued since publication. No human clinical trials have been reported yet, but the preclinical foundation established here remains relevant to the ongoing search for glaucoma neuroprotective therapies.
The bigger picture
Neuroprotection has been the holy grail of glaucoma research for decades. While lowering eye pressure helps, many patients continue to lose vision because the underlying nerve cell death isn't addressed. Peptain-1 joins a growing list of neuroprotective peptides being investigated for eye disease, but its ability to cross the blood-retinal barrier after systemic injection sets it apart. If it reaches human trials, it could be the first neuroprotective therapy for glaucoma — a fundamentally different treatment than anything currently available.
Questions still open
- Can peptain-1 protect retinal ganglion cells in human glaucoma, where the disease progresses over years rather than weeks?
- What is the optimal dosing schedule for sustained neuroprotection, and does the effect persist after stopping treatment?
- Could peptain-1 be combined with pressure-lowering drugs for a dual-mechanism approach to glaucoma?
Common questions
Why is neuroprotection important for glaucoma?
Why is it significant that peptain-1 crosses the blood-retinal barrier?
Read the original research
Systemically administered peptain-1 inhibits retinal ganglion cell death in animal models: implications for neuroprotection in glaucoma.
Cell death discovery, 5, 112
Citation
Stankowska, Dorota L; Nam, Mi-Hyun; Nahomi, Rooban B; Chaphalkar, Renuka M; Nandi, Sandip K; Fudala, Rafal; Krishnamoorthy, Raghu R; Nagaraj, Ram H. (2019). Systemically administered peptain-1 inhibits retinal ganglion cell death in animal models: implications for neuroprotection in glaucoma.. Cell death discovery, 5, 112. https://doi.org/10.1038/s41420-019-0194-2